SCHEMBL27433248

SCHEMBL27433248

COc1c(F)cc2c(c1C(=O)O)OCCN2C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.36
KCNA3 P22001 1/20 0.36
CPT2 P23786 3/20 0.34
CPT1A P50416 3/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
CPT1B Q92523 2/20 0.33
HTR6 P50406 1/20 0.32
NPC1 O15118 1/20 0.32
PKM P14618 1/20 0.32
PKLR P30613 1/20 0.32
RAB9A P51151 1/20 0.32
POLB P06746 1/20 0.32
LMNA P02545 1/20 0.32
THRB P10828 1/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
GFER P55789 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30954082 1.00 RXFP1 (0.36) RXFP1KCNA3CPT2CPT1APDE4A
SCHEMBL27434460 0.87 RXFP1 (0.42) RXFP1KCNA3CPT2CPT1ACPT1B
SCHEMBL30954108 0.85 KDM4E (0.43) RXFP1CPT2CPT1ACPT1BALDH1A1
SCHEMBL27432464 0.85 KDM4E (0.43) RXFP1CPT2CPT1ACPT1BALDH1A1
SCHEMBL27432574 0.82 DRD2 (0.35) CPT2CPT1ACPT1BNPC1PKM
SCHEMBL27435005 0.79 KCNA3 (0.42) KCNA3POLBLMNAMEN1KMT2A
SCHEMBL27432942 0.78 KDM4E (0.41) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL30954043 0.78 KDM4E (0.41) NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1
SCHEMBL30954119 0.77 NOTUM (0.38) NPC1PKMPKLRRAB9APOLB
SCHEMBL27432668 0.77 NOTUM (0.38) NPC1PKMPKLRRAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP claimed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO claimed
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed